We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pivotal Study in Advanced Parkinsons Disease Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00466167
First Posted: April 27, 2007
Last Update Posted: July 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
  Purpose

The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined), safety, and tolerability of pramipexole ER, in daily doses from 0.375 milligram to 4.5 milligram once a day, in comparison to placebo, in Levodopa combined with a Dopa-Decarboxylase-inhibitor treated Parkinson patients with advanced Parkinsons Disease and motor fluctuations.

In addition, a numerical comparison of the efficacy of pramipexole extended release versus pramipexole immediate release will be done.

The efficacy of pramipexole immediate release will also be compared to placebo, for assay sensitivity.


Condition Intervention Phase
Parkinson Disease Drug: Pramipexol Extended Release Drug: Pramipexol Immediate Release Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18 [ Time Frame: baseline and week 18 ]
    UPDRS II+III total score on Full Analysis Set (FAS)with LOCF (Last observation carried forward), week 18 - baseline, UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms


Secondary Outcome Measures:
  • Change From Baseline in Percentage Off-time at Week 18 [ Time Frame: baseline and week 18 ]
    Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).

  • Change From Baseline in Percentage On-time Without Dyskinesia at Week 18 [ Time Frame: baseline and week 18 ]
    Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  • Change From Baseline in Percentage On-time With Non-troublesome Dyskinesia at Week 18 [ Time Frame: baseline and week 18 ]
    Percentage on-time with non-troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  • Change From Baseline in Percentage On-time With Troublesome Dyskinesia at Week 18 [ Time Frame: baseline and week 18 ]
    Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). On-time describes a period when the patient has no symptoms of off-time and is not asleep.

  • Clinical Global Impression - Global Improvement (CGI-I) Responder [ Time Frame: after 18 weeks of treatment ]
    CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring of 1 or 2 (at least much improved)

  • Response in Patient Global Impression (PGI-I) [ Time Frame: after 18 weeks of treatment ]
    PGI-I scores ranging from '1' (very much better) to '7' (very much worse), PGI-I responder have scoring 1 or 2 (at least much better)

  • Change From Baseline in UPDRS I Score After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood

  • Change From Baseline in UPDRS II Score After 18 Weeks, Average at on and Off-period [ Time Frame: baseline and 18 weeks ]
    UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities.

  • Change From Baseline in UPDRS III Score After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms

  • Change From Baseline in UPDRS IV Score After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy

  • Change From Baseline in Beck's Depression Inventory (BDI) After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    ranging from 0 (best case) to 63 (worst case)

  • Change From Baseline in Parkinson's Disease Sleep Scale (PDSS) After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    ranging from 0 (worst case) to 150 (best case)

  • Change From Baseline in Parkinson's Disease Quality of Life Questionnaire 39 After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    Ranging from 0 (best case) to 156 (worst case)

  • Change From Baseline in European Quality of Life (EuroQol) Scale After 18 Weeks [ Time Frame: baseline and 18 weeks ]
    ranging from 0 (worst case) to 100 (best case)

  • Change From Baseline in 11-point Likert Scale for Pain Related to PD at Week 18 [ Time Frame: baseline and week 18 ]
    Likert scale is a method used for the measurement of pain. The patients were asked to rate their pain related to PD by ticking the number that best described their pain on the average in the previous week, from zero for "no pain" to ten for "unbearable pain".

  • Clinically Significant Abnormalities: Clinical Laboratory Evaluations (Biochemistry and Haematology) [ Time Frame: baseline and week 18 ]

Enrollment: 517
Study Start Date: April 2007
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Pramipexole ER Drug: Pramipexol Extended Release
Pramipexole IR Drug: Pramipexol Immediate Release
Placebo Comparator: Placebo Drug: Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   32 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patient with advanced idiopathic Parkinsons disease confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.
  2. Parkinsons disease diagnosed for at least 2 years.
  3. Patients 30 years of age or older at the time of diagnosis.
  4. Modified Hoehn and Yahr stage of 2 to 4 at on-time.
  5. Treatment with standard or controlled release Levodopa combined with a Dopa-Decarboxylase-inhibitor, or with Levodopa combined with a Dopa-Decarboxylase-inhibitor/entacapone, at an optimised dose according to investigators judgement, this dose being stable for at least 4 weeks prior to baseline visit.
  6. Motor fluctuations, with at least 2 cumulative hours of off-time every day during waking hours (documented on a patient diary completed for 2 consecutive days before baseline visit).
  7. Patient willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. In particular, after training, it has to be documented at baseline visit that the patient is able to recognise the off-time and on-time periods during waking hours and that the patient (or a family member or a guardian) is able to record them accurately in the patient diary.
  8. Signed informed consent obtained before any study procedures are carried out (in accordance with International Conference on Harmonisation-Good Clinical Practice guidelines and local legislation).

Exclusion Criteria:

  1. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or degenerative diseases
  2. Dementia, as defined by a Mini-Mental State Exam score < 24 at screening visit
  3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria that could prevent compliance or completion of the study and/or put the patient at risk if he/she takes part in the study
  4. History of psychosis, except history of drug induced hallucinations
  5. History of deep brain stimulation
  6. Clinically significant Electrocardiogram abnormalities at screening visit
  7. Clinically significant hypotension and/or symptomatic orthostatic hypotension at screening or baseline visit
  8. Malignant melanoma or history of previously treated malignant melanoma
  9. Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study
  10. Pregnancy or breast-feeding
  11. Sexually active female of childbearing potential not using a medically approved method of birth control for at least one month prior to the screening visit and throughout the study period
  12. Serum levels of Aspartate Aminotransferase (Serum Glutamic-Oxaloacetic Transaminase), Alanine Aminotransferase (Serum Glutamic Pyruvic Transaminase), alkaline phosphatases or bilirubin > 2 Upper Limit of Normal
  13. Patients with a creatinine clearance < 50 millilitres/minute
  14. Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit
  15. Any medication with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit
  16. Any of the following drugs within 4 weeks prior to baseline visit: methylphenidate, cinnarizine, amphetamines
  17. Flunarizine within 3 months prior to baseline visit
  18. Known hypersensitivity to pramipexole or its excipients
  19. Drug abuse according to investigators judgement, within 2 years prior to screening
  20. Participation in other investigational drug studies, or use of other investigational drugs within one month or five times the half-life of the investigational drug (whichever is longer) prior to baseline visit
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00466167


  Show 76 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00466167     History of Changes
Other Study ID Numbers: 248.525
First Submitted: April 25, 2007
First Posted: April 27, 2007
Results First Submitted: November 17, 2009
Results First Posted: February 8, 2010
Last Update Posted: July 8, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Pramipexole
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents